STOCK TITAN

[Form 4] Mesa Laboratories Inc Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Mesa Laboratories (NASDAQ:MLAB) CFO John Sakys reported multiple transactions on June 21, 2025. The transactions involved the vesting of 1,036 Restricted Stock Units (RSUs) and subsequent sale of 454 shares for tax withholding purposes at $95.82 per share. Following these transactions, Sakys directly owns 15,044 shares and indirectly holds 100 shares as custodian for his children.

John Sakys, CFO di Mesa Laboratories (NASDAQ:MLAB), ha comunicato diverse operazioni il 21 giugno 2025. Le operazioni hanno riguardato la maturazione di 1.036 Restricted Stock Units (RSU) e la successiva vendita di 454 azioni per coprire le imposte, al prezzo di 95,82 dollari per azione. Dopo queste operazioni, Sakys possiede direttamente 15.044 azioni e detiene indirettamente 100 azioni come tutore per i suoi figli.

John Sakys, CFO de Mesa Laboratories (NASDAQ:MLAB), informó múltiples transacciones el 21 de junio de 2025. Las transacciones involucraron la consolidación de 1,036 Unidades de Acciones Restringidas (RSUs) y la venta posterior de 454 acciones para cubrir retenciones fiscales a un precio de 95,82 dólares por acción. Tras estas operaciones, Sakys posee directamente 15,044 acciones y mantiene indirectamente 100 acciones como custodio para sus hijos.

Mesa Laboratories (NASDAQ:MLAB)의 CFO John Sakys는 2025년 6월 21일 여러 거래를 보고했습니다. 이 거래들은 1,036개의 제한 주식 단위(RSU)의 취득과 세금 원천징수를 위해 454주를 주당 95.82달러에 매도하는 내용이 포함되어 있습니다. 이 거래 후 Sakys는 직접적으로 15,044주를 보유하고 있으며, 자녀들을 위해 100주를 간접적으로 관리하고 있습니다.

John Sakys, directeur financier de Mesa Laboratories (NASDAQ:MLAB), a déclaré plusieurs opérations le 21 juin 2025. Ces opérations concernaient la levée de 1 036 unités d’actions restreintes (RSU) et la vente subséquente de 454 actions pour couvrir les retenues fiscales, au prix de 95,82 dollars par action. À la suite de ces transactions, Sakys possède directement 15 044 actions et détient indirectement 100 actions en tant que tuteur pour ses enfants.

John Sakys, CFO von Mesa Laboratories (NASDAQ:MLAB), meldete am 21. Juni 2025 mehrere Transaktionen. Die Vorgänge betrafen das Vesting von 1.036 Restricted Stock Units (RSUs) und den anschließenden Verkauf von 454 Aktien zum Zweck der Steuerabführung zu einem Kurs von 95,82 USD pro Aktie. Nach diesen Transaktionen besitzt Sakys direkt 15.044 Aktien und hält indirekt 100 Aktien als Treuhänder für seine Kinder.

Positive
  • None.
Negative
  • None.

Insights

Standard RSU vesting and tax-related share sale indicates normal executive compensation activity with no concerning signals.

The reported transactions represent a routine vesting event of RSUs granted as part of the CFO's compensation package. The immediate sale of 454 shares (approximately 44% of vested shares) appears to be solely for covering tax obligations, a common practice among executives. The retention of the majority of vested shares (56%) demonstrates continued alignment with shareholder interests. The CFO maintains a significant equity position with 15,044 shares held directly, suggesting strong confidence in the company's prospects.

John Sakys, CFO di Mesa Laboratories (NASDAQ:MLAB), ha comunicato diverse operazioni il 21 giugno 2025. Le operazioni hanno riguardato la maturazione di 1.036 Restricted Stock Units (RSU) e la successiva vendita di 454 azioni per coprire le imposte, al prezzo di 95,82 dollari per azione. Dopo queste operazioni, Sakys possiede direttamente 15.044 azioni e detiene indirettamente 100 azioni come tutore per i suoi figli.

John Sakys, CFO de Mesa Laboratories (NASDAQ:MLAB), informó múltiples transacciones el 21 de junio de 2025. Las transacciones involucraron la consolidación de 1,036 Unidades de Acciones Restringidas (RSUs) y la venta posterior de 454 acciones para cubrir retenciones fiscales a un precio de 95,82 dólares por acción. Tras estas operaciones, Sakys posee directamente 15,044 acciones y mantiene indirectamente 100 acciones como custodio para sus hijos.

Mesa Laboratories (NASDAQ:MLAB)의 CFO John Sakys는 2025년 6월 21일 여러 거래를 보고했습니다. 이 거래들은 1,036개의 제한 주식 단위(RSU)의 취득과 세금 원천징수를 위해 454주를 주당 95.82달러에 매도하는 내용이 포함되어 있습니다. 이 거래 후 Sakys는 직접적으로 15,044주를 보유하고 있으며, 자녀들을 위해 100주를 간접적으로 관리하고 있습니다.

John Sakys, directeur financier de Mesa Laboratories (NASDAQ:MLAB), a déclaré plusieurs opérations le 21 juin 2025. Ces opérations concernaient la levée de 1 036 unités d’actions restreintes (RSU) et la vente subséquente de 454 actions pour couvrir les retenues fiscales, au prix de 95,82 dollars par action. À la suite de ces transactions, Sakys possède directement 15 044 actions et détient indirectement 100 actions en tant que tuteur pour ses enfants.

John Sakys, CFO von Mesa Laboratories (NASDAQ:MLAB), meldete am 21. Juni 2025 mehrere Transaktionen. Die Vorgänge betrafen das Vesting von 1.036 Restricted Stock Units (RSUs) und den anschließenden Verkauf von 454 Aktien zum Zweck der Steuerabführung zu einem Kurs von 95,82 USD pro Aktie. Nach diesen Transaktionen besitzt Sakys direkt 15.044 Aktien und hält indirekt 100 Aktien als Treuhänder für seine Kinder.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sakys John

(Last) (First) (Middle)
MESA LABORATORIES, INC.
12100 W. 6TH AVENUE

(Street)
LAKEWOOD CO 80228

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MESA LABORATORIES INC /CO/ [ MLAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
06/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/21/2025 M 1,036 A $95.82 15,498 D
Common Stock 06/21/2025 F 454 D $95.82 15,044 D
Common Stock 100 I Custodian(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units - 6 (1) 06/21/2025 M 1,036 (2) (3) Common Stock 1,036 $0 1,036 D
Explanation of Responses:
1. Each RSU represents a contingent right to receive one share of the Issuer's common stock
2. RSUs that vest 1/3 on June 21, 2024 and each of the next two anniversary dates
3. Not Applicable
4. Consists of 100 shares held by children of which Mr. Sakys is custodian
John Sakys 06/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Mesa Laboratories

NASDAQ:MLAB

MLAB Rankings

MLAB Latest News

MLAB Latest SEC Filings

MLAB Stock Data

522.74M
5.13M
5.75%
95.91%
3.66%
Scientific & Technical Instruments
Industrial Instruments for Measurement, Display, and Control
Link
United States
LAKEWOOD